Restraining CDK1-cyclin B Activation: PP2A on the CUSP(7)
Overview
Molecular Biology
Affiliations
USP7 inhibitors are gaining momentum as a therapeutic strategy to stabilize p53 through their ability to induce MDM2 degradation. However, these inhibitors come with an unexpected p53-independent toxicity, via an unknown mechanism. In this issue of The EMBO Journal, Galarreta et al report how inhibition of USP7 leads to re-distribution of PP2A from cytoplasm to nucleus and an increase of deleterious CDK1-dependent phosphorylation throughout the cell cycle, revealing a new regulatory mechanism for the progression of S-phase cells toward mitosis to maintain genomic integrity.
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond.
Wu Q, Nandi D, Sharma D Cancer Metastasis Rev. 2024; 44(1):16.
PMID: 39644332 PMC: 11625080. DOI: 10.1007/s10555-024-10226-2.
Restraining CDK1-cyclin B activation: PP2A on the cUSP(7).
Chow-Castro M, Dixon S, Saldivar J EMBO J. 2021; 40(11):e108486.
PMID: 33969907 PMC: 8167361. DOI: 10.15252/embj.2021108486.